Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF | V.TLT.WT

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by Quattro74on May 04, 2020 12:23am
100 Views
Post# 30982264

RE:RE:RE:RE:The Longest Day

RE:RE:RE:RE:The Longest Day
Yeah Doc, I'm with ya here too. If for some odd reason things get really stalled in Canada, a high % of the first 12 at 1 yr CR would still get their attention, especially if it is only off of a single treatmet. I don't expect that to happen, I actually think things will begin to get back to normal once we get the hot summer weather.

Hempdoc wrote:

Based on the typical summer slumber for respiratory viruses & more hospitals being opened for business, it shouldn't be too difficult to get 20 patients treated by end of fall (especially if the US is on board)...& just before the typical late fall/winter wave of resp. viruses.  

Any long term run needs confirmatory data.  Canadian data helps, but opening those American doors can pretty much guarantee a doubling or tripling of our current pace = significantly faster path to statistical significance.  That IND approval thus carries a lot of weight/value based on anticipated results (at least in our eyes).  But a "sustained run" on this exchange without accompanying solid 6 month/1 yr data in more than "a few" patients...not likely going to happen imo....maybe get a bump up to $0.40.  Ultimately, the IND approval is only as good as the data it enables & where it's enabled.  I believe once we get solid confirmatory American data (my guess...at least 6 to 10 patients), we will have more than enough reason to celebrate in Vegas.  However, 10 to 12/12 Canadian with IND in hand should get us past Barstow....JMO.  Good luck...



Bullboard Posts